Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 12,073 | 14,552 | 11,992 | 13,995 | 15,711 |
| Other current assets | 0 | 0 | 71 | 0 | 0 |
| TOTAL | $12,199 | $14,624 | $12,148 | $14,147 | $15,961 |
| Non-Current Assets | |||||
| PPE Net | 71 | 78 | 65 | 71 | 78 |
| TOTAL | $71 | $78 | $65 | $71 | $78 |
| Total Assets | $12,270 | $14,702 | $12,213 | $14,219 | $16,039 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,281 | 1,682 | 1,360 | 1,257 | 914 |
| Accrued Expenses | 8,454 | 620 | 1,153 | 1,022 | 497 |
| Other current liabilities | 11 | 15 | 141 | 210 | 302 |
| TOTAL | $11,129 | $5,229 | $5,565 | $5,400 | $4,624 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 1,383 | 2,911 | 2,911 | 2,911 | 2,911 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $11,129 | $5,229 | $5,565 | $5,400 | $4,624 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 9 | 9 | 9 | 1 | 1 |
| Common Shares | 2 | 2 | 0 | 6 | 6 |
| Retained earnings | -36,538 | -28,149 | -25,467 | -23,264 | -20,636 |
| TOTAL | $1,140 | $9,473 | $6,648 | $8,819 | $11,415 |
| Total Liabilities And Equity | $12,270 | $14,702 | $12,213 | $14,219 | $16,039 |